Review of “Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review”
Given the growing prominence of advanced therapy medicinal products (ATMPs) expected to reach patients in the coming years, it is important to conduct further research in this space to understand all potential impacts and considerations of their economic evaluation. To support this, for my next few blog posts, I will review papers published as part…
Preferences for advanced therapy medicinal products: understanding the published literature on the value of innovative health interventions
Advanced therapy medicinal products (ATMPs) are ground-breaking genetic and cell/tissue-based therapies with the potential to treat and cure myriad health conditions (1,2). However, they have faced multiple challenges in decision making with relatively low success in achieving reimbursement (3-7). As such, there may be a disconnect between existing value assessment frameworks which Health Technology Assessment…
Ending the confusion: defining key terms in value assessment
Recent conversations have highlighted the lack of understanding in the industry of key terms common to discussions of value assessment. As a Health Economist passionate about value assessment and an active researcher in this space, this sparked a desire to write a blog post laying out these terms and their definitions to support the development…
All NFHealthEconomics posts
Check out all my blog posts:
https://nf-health-economics.com/author/nfhealtheconomics/
Follow My Blog
Get new content delivered directly to your inbox.
Nermina Ferizovic | Health Economics Expert 